300725SZSE

2025 Annual Report of Independent Director (Jin Li)

PharmaBlock Sciences (Nanjing) , Inc.··8 pages

✨ AI Summary

This report details the independent director's performance in 2025, covering attendance at board and shareholder meetings, participation in independent director committee meetings, and committee work. The director actively reviewed proposals, provided opinions, and exercised voting rights to safeguard shareholder interests, particularly those of small and medium shareholders. The director also engaged in communication with internal audit and external auditors.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Nanjing Dajin Technology Co., Ltd. 2025 Annual Report of Independent Director (Jin Li)

As an independent director of Nanjing Dajin Technology Co., Ltd. (hereinafter referred to as the "Company"), I have strictly complied with the Company Law, Securities Law, Corporate Governance Guidelines for Listed Companies, Shenzhen Stock Exchange's Self-Regulatory Guidelines No. 2 for Listed Companies on the ChiNext Market, "Management Measures for Independent Directors of Listed Companies (2025 Revision)," and the "Company Articles of Association," and the "Work System for Independent Directors of the Company," etc. I have diligently and faithfully performed my duties, fully utilized my role as an independent director, and protected the legitimate rights and interests of the Company and all shareholders, especially small and medium shareholders. The report on my performance in 2025 is as follows:

I. Personal Information

During the reporting period, I met the independence requirements stipulated in Article 6 of the "Management Measures for Independent Directors of Listed Companies" and there were no circumstances affecting my independence. My resume is as follows:

Born in 1973, Chinese national, without permanent overseas residency, with a Master's degree. Currently a senior partner at Deheng Law Offices (Nanjing). With over twenty years of practice, I was selected as a leading talent in foreign-related law by the All China Lawyers Association. I have received multiple industry honors, such as Jiangsu Province Outstanding Lawyer. I have attended training sessions on international trade law, international investment, and cross-border mergers and acquisitions organized by the Ministry of Justice of China, the All China Lawyers Association, and the Jiangsu Lawyers Association multiple times. I have engaged in academic exchanges as a visiting scholar at the University of Maryland, Georgetown University, and the International Law Society in the United States. I specialize in legal affairs related to company financing, mergers and acquisitions, foreign-related law, and intellectual property rights, both litigation and non-litigation. I have been appointed as an arbitrator by several well-known arbitration commissions, including Nanjing, Changzhou, Dalian, and Urumqi Arbitration Commissions, and as a mediator at the China International Chamber of Commerce Mediation Center and the Belt and Road International Commercial Mediation Center. I am also a member of the professional committees of the Jiangsu Lawyers Association and the Nanjing Lawyers Association. I have served as an independent director of the Company since November 29, 2021.

II. Performance During the Reporting Period

(I) Attendance at Board Meetings and Shareholder Meetings

From January 1, 2025, to December 31, 2025, the Company held 10 board meetings and 2 shareholder meetings. My attendance record is as follows:

Independent Director NameNumber of Board Meetings AttendedNumber of Board Meetings Actually AttendedNumber of AbsencesNumber of Entrusted AttendanceWhether Personally Attended Consecutive MeetingsNumber of Shareholder Meetings to AttendNumber of Shareholder Meetings Actually Attended
Jin Li101000No22

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.